British researchers after the rollout of inoculations were disrupted by reports of rare clots released a statement on Thursday that the risk of blood clots from COVID-19 infections are much higher than from vaccines against the disease.

AstraZeneca and Johnson & Johnson have seen some uncommon reports of cerebral venous sinus thrombosis (CVST) linked to their vaccines. The United States on this Wednesday paused vaccinations using J&J’s shot when a link with clots was investigated.

British vaccine regulators have emphasized to the fact that the benefits of vaccination will outweigh the risks.

A study based on 500,000 COVID-19 patients revealed CVST occurred at a rate of 39 in a million peoples because of infection. But with European Medicines Agency (EMA) it is only 5 in a million that were reported CVST after getting AstraZeneca’s doses.

A pre-print study revealed that the risk of CVST can be 8-10 times higher if you had COVID-19 infection in the past than it was from existing vaccines for the disease. Mortality rate from CVST was around 20% whether it occurred after COVID-19 infection or a vaccine, showing the clots were the primary risk factor.

Oxford University said that they have worked independently from the Oxford vaccine team to develop this AstraZeneca.

The research team, from Oxford University, said they worked independently from the Oxford vaccine team to develop this AstraZeneca shot. The importance of this research is to bring back the fact that this is a really horrible illness, together with the increased risk of CVST.